Pulmonary function in patients receiving long-term low-dose methotrexate

Chest

Volumn 109, Issue 4, 1996, Pages 933-938

  Cottin, Vincent ^a   Tébib, Jacques ^a   Massonnet, Bernard ^a   Souquet, Pierre Jean ^a   Bernard, Jean Pierre ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

adverse effects; carbon monoxide; diffusion capacity; methotrexate; methotrexate pneumonitis; pulmonary function tests

Indexed keywords

METHOTREXATE; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INTERSTITIAL PNEUMONIA; INTRAMUSCULAR DRUG ADMINISTRATION; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATIC DISEASE; RISK FACTOR;

EID: 0029863825     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.109.4.933     Document Type: Article

References (34)

1. Jolivet J, Cowan KH, Curt GA, et al. The pharmacology and clinical use of methotrexate. N Engl J Med 1983; 309:1094-1104
2. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312:818-22
3. Williams HJ, Willkens RF, Samuelson CO, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1985; 28:721-29
4. Weinstein A, Marlowe S, Korn J, et al. Low dose methotrexate treatment of rheumatoid arthritis. Am J Med 1985; 79:331-37
5. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months. Arthritis Rheum 1992; 35:138-45
6. Sostman HD, Matthay RA, Putman CE. Methotrexate-induced pneumonitis. Medicine 1976; 55:371-88
7. Cooper JAD, White DA, Matthay RA. Drug-induced pulmonary disease: I. Cytotoxic drugs. Am Rev Respir Dis 1986; 133:321-40
8. Engelbrecht JA, Calhoon SL, Scherrer JJ. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis. Arthritis Rheum 1983; 26:1275-78
9. Cannon GW, Ward JR, Clegg DO, et al. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rhenm 1983; 26:1269-73
10. St Clair EW, Rice JR, Snyderman R. Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. Arch Intern Med 1985; 145:2035-38
11. Louie S, Lillington GA. Low dose methotrexate pneumonitis in rheumatoid arthritis. Thorax 1986; 41:703-04
12. Cook NJ, Carroll GJ. Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis. Ann Rheum Dis 1992; 51:272-74
13. Hargreaves MR, Mowat AG, Benson MK. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax 1992; 47:628-33
14. Barrera P, Laan RFJM, van Riel PLCM, et al. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994; 53:434-39
15. Van Barneveld PWC, Van Der Mark TW, Sleijfer DT, et al. Predictive factors for bleomycin-induced pneumonitis. Am Rev Respir Dis 1984; 130:1078-81
16. Searles G, Mc Kendry RJR. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors: four case reports and a review of the literature. J Rheumatol 1987; 14:1164-71
17. Crapo RO, Gardner RM. Single breath carbon monoxide diffusing capacity (transfer factor): recommendations for a standard technique. Am Rev Respir Dis 1987; 136:1299-1307
18. Cotes JE, Dabbs JM, Elwood PC, et al. Iron-deficiency anaemia: its effect on transfer factor for the lung (diffusing capacity) and ventilation and cardiac frequency during sub-maximal exercise. Clin Sci 1972; 42:325-35
19. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Eur Respir J 1993; 6(suppl 16):5-40
20. Cotes JE, Chinn DJ, Quanjer PH, et al. Standardization of the measurement of transfer factor (diffusing capacity). Eur Respir J 1993; 6(suppl 16):41-52
21. Dean AD, Dean JA, Burton JH, et al. Epi info, version 5: a word processing, database, and statistics program for epidemiology on micro-computers. Atlanta: Centers for Disease Control, 1990
22. Buchbinder R, Hall S, Sambrook PN, et al. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol 1993; 20:639-44
23. Drosos AA, Psychos D, Andonopoulos AP, et al. Methotrexate therapy in rheumatoid arthritis: a 2-year prospective follow-up. Clin Rheumatol 1990; 9:333-41
24. Weinblatt ME, Weissman BN, Holdsworth DED, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis, 84-month update. Arthritis Rheum 1992; 35:129-37
25. Jones G, Mierins E, Karsh J. Methotrexate-induced asthma. Am Rev Respir Dis 1991; 143:179-81
26. Wollner A, Mohle-Boetani J, Lambert RE, et al. Pneumocystis carinii pneumonia complicating low-dose methotrexate treatment for rheumatoid arthritis. Thorax 1991; 46:205-07
27. Wall MA, Wohl MEB, Jaffe N, et al. Lung function in adolescents receiving high-dose methotrexate. Pediatrics 1979; 63:741-46
28. Phillips TJ, Wallis PJ, Jones DH, et al. Pulmonary function in patients on long-term, low-dose methotrexate. Br J Dermatol 1986; 115:657-62
29. Pelucchi A, Lomater C, Gerloni V, et al. Lung function and diffusing capacity for carbon monoxide in patients with juvenile chronic arthritis: effect of disease activity and low dose methotrexate therapy. Clin Exp Rheumatol 1994; 12:675-79
30. Jeurissen MEC, Boerbooms AMT, Festen J, et al. Pulmonary function tests in rheumatoid arthritis: a double blind study of azathioprine and methotrexate [abstract]. Arthritis Rheum 1991; 34:A146
31. Crook AD, Furst DF, Helmers RA, et al. Methotrexate does not alter pulmonary function in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1989; 32:S60
32. Andersen PA, West SG, O'Dell JR, et al. Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunological effects in a randomized, double-blind study. Ann Intern Med 1985; 103:489-96
33. Thompson RN, Watts C, Edelman J, et al. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 1984; 11:760-63
34. Scott DGI, Bacon PA. Response to methotrexate in fibrosing alveolitis associated with connective tissue disease. Thorax 1980; 35:725-32